CALGARY, June 27, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today
announced that its Phase 2b ASSURE clinical trial evaluating RVX-208 in
high-risk cardiovascular patients with low high-density lipoprotein
(HDL) did not meet its primary endpoint of a -0.6% change in percent
atheroma volume as determined by intravascular ultrasound (IVUS). The
RVX-208 treated group had -0.4% plaque regression (p= 0.08). RVX-208 is
Resverlogix's first-in-class orally active BET-protein inhibitor.
The patient group receiving active treatment met the secondary endpoints
of regression of total (coronary) atheroma volume (TAV) and increases
in Apolipoprotein A-I (ApoA-I) and HDL cholesterol. Unexpected strong
placebo results will need to be further explored.
ASSURE, a 26-week, multi-center, double-blind, randomized, parallel
group, placebo-controlled trial enrolled 324 patients and was led by
the Cleveland Clinic. The secondary endpoints for ASSURE included
safety and tolerability of RVX-208, effects of the compound on plasma
ApoA-I, HDL cholesterol, HDL-subclasses and non-HDL lipid parameters.
"Together with the study's principal investigators, we remain focused on
analyzing the full data set over the coming weeks and months to
determine whether continued development of RVX-208 in cardiovascular
disease is warranted," said Donald McCaffrey, president and chief
executive officer of Resverlogix.
About RVX-208
RVX-208 is a first-in-class small molecule that inhibits BET
bromodomains. RVX-208 functions by removing atherosclerotic plaque via
reverse cholesterol transport (RCT), the natural process through which
atherosclerotic plaque is transported out of the arteries and removed
from the body by the liver. RVX-208 increases production of ApoA-I, the
key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT.
These newly produced, functional HDL particles are flat and empty and
can efficiently remove plaque and stabilize or reverse atherosclerotic
disease. ApoA-I may also exert beneficial effects in Alzheimer's
disease and Diabetes Mellitus.
About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company
developing compounds involving a therapeutic increase in ApoA-I.
Resverlogix's RVX-208 is a first-in-class small molecule for the
treatment of atherosclerosis and other chronic diseases such as
diabetes mellitus and Alzheimer's disease. RVX-208 is the first BET
bromodomain inhibitor in clinical trials. Resverlogix's common shares
trade on the Toronto Stock Exchange (TSX: RVX). For further information
please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
Company Contacts:
|
|
|
Donald J. McCaffrey
|
Sarah Zapotichny
|
President and CEO
|
Director of Investor Relations
|
Resverlogix Corp.
|
Resverlogix Corp.
|
Phone: 403-254-9252
|
Phone: 403-254-9252
|
Email: don@resverlogix.com
|
Email: sarah@resverlogix.com
|
|
|
US Institutional Investors:
|
Media:
|
|
|
Susan Noonan
|
Andreas Marathovouniotis
|
Managing Partner
|
Account Supervisor
|
S.A. Noonan Communications, LLC
|
Russo Partners, LLC
|
Phone: 212-966-3650
|
Phone: 212-845-4235
|
Email: susan@sanoonan.com
|
Email: andreas.marathis@russopartnersllc.com
|
SOURCE Resverlogix Corp.